In conclusion, in the phase 2 RESCUE trial, the IL-6 ligand antibody ziltivekimab significantly improved the levels of Hb, serum iron, total iron-binding capacity, and transferrin saturation versus placebo in patients with CKD stage 3–5. Here, TF is linked to chronic kidney disease.